SCHEMBL4677312

SCHEMBL4677312

COc1cc(-c2cc3nnc(Nc4ccncc4)nc3n(C3CCCC3)c2=O)cc(OC)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.56
FGFR2 P21802 1/20 0.56
FGFR4 P22455 1/20 0.56
FGFR3 P22607 1/20 0.56
KDR P35968 1/20 0.56
PIK3CA P42336 9/20 0.45
MTOR P42345 3/20 0.45
CYP1A2 P05177 4/20 0.41
CDK4 P11802 3/20 0.41
CASP1 P29466 3/20 0.41
CASP7 P55210 3/20 0.41
USP2 O75604 3/20 0.41
CDK6 Q00534 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP2C9 P11712 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41
CCNA2 P20248 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678419 0.91 FGFR1 (0.68) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL4679796 0.87 FGFR1 (0.46) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL4682230 0.84 FGFR4 (0.48) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL4677376 0.83 FGFR1 (0.47) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL4680717 0.83 FGFR4 (0.48) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL4677844 0.82 FGFR1 (0.52) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL4677251 0.81 FGFR1 (0.82) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL4680419 0.81 FGFR1 (0.51) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL4713584 0.78 NUAK1 (0.62) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL4679189 0.76 PIK3CA (0.44) FGFR1FGFR2FGFR4FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1195378-B1 Pyridotriazines and pyridopyridazines WARNER LAMBERT CO (US) 2008-01-23 EP claimed
US-6683183-B2 BICYCLIC HETEROCYCLES THAT INHIBIT CYCLIN-DEPENDENT KINASE OR TYROSINE KINASE ENZYMES, OR BOTH, FOR TREATMENT OF PROLIFERATIVE DISORDERS WARNER-LAMBERT COMPANY 2004-01-27 US claimed
US-20020061865-A1 Pyridotriazines and pyridopyridazines KRAMER JAMES BERNARD (US) 2002-05-23 US claimed
EP-1195378-A1 Pyridotriazines and pyridopyridazines WARNER-LAMBERT COMPANY (US) 2002-04-10 EP claimed
EP-1195378-B1 Pyridotriazines and pyridopyridazines WARNER LAMBERT CO (US) 2008-01-23 EP disclosed
US-6683183-B2 BICYCLIC HETEROCYCLES THAT INHIBIT CYCLIN-DEPENDENT KINASE OR TYROSINE KINASE ENZYMES, OR BOTH, FOR TREATMENT OF PROLIFERATIVE DISORDERS WARNER-LAMBERT COMPANY 2004-01-27 US disclosed
US-20020061865-A1 Pyridotriazines and pyridopyridazines KRAMER JAMES BERNARD (US) 2002-05-23 US disclosed
EP-1195378-A1 Pyridotriazines and pyridopyridazines WARNER-LAMBERT COMPANY (US) 2002-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061865-A1 Pyridotriazines and pyridopyridazines CDK1, CDK4, CDK2 FGFR1 194/4885FGFR2 694/4885FGFR4 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.